BRPI0822572A2 - Terapia guiada por imagem de doença moicardial, composição manufaturamento e aplicações - Google Patents

Terapia guiada por imagem de doença moicardial, composição manufaturamento e aplicações

Info

Publication number
BRPI0822572A2
BRPI0822572A2 BRPI0822572-9A BRPI0822572A BRPI0822572A2 BR PI0822572 A2 BRPI0822572 A2 BR PI0822572A2 BR PI0822572 A BRPI0822572 A BR PI0822572A BR PI0822572 A2 BRPI0822572 A2 BR PI0822572A2
Authority
BR
Brazil
Prior art keywords
moicardial
applications
manufacturing composition
guided therapy
imaging guided
Prior art date
Application number
BRPI0822572-9A
Other languages
English (en)
Inventor
David J Yang
Chang Sok Oh
Saady Kohanim
Dong-Fang Yu
E Edmund Kim
Richard Mendez
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BRPI0822572A2 publication Critical patent/BRPI0822572A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0822572-9A 2008-03-24 2008-12-19 Terapia guiada por imagem de doença moicardial, composição manufaturamento e aplicações BRPI0822572A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3897308P 2008-03-24 2008-03-24
PCT/US2008/087777 WO2009120244A1 (en) 2008-03-24 2008-12-19 Image-guided therapy of myocardial disease: composition, manufacturing and applications

Publications (1)

Publication Number Publication Date
BRPI0822572A2 true BRPI0822572A2 (pt) 2015-06-23

Family

ID=41089134

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822572-9A BRPI0822572A2 (pt) 2008-03-24 2008-12-19 Terapia guiada por imagem de doença moicardial, composição manufaturamento e aplicações

Country Status (9)

Country Link
US (2) US8440168B2 (pt)
EP (1) EP2268320A4 (pt)
JP (1) JP2011515467A (pt)
KR (1) KR20100127845A (pt)
CN (1) CN102159253A (pt)
AU (1) AU2008353360A1 (pt)
BR (1) BRPI0822572A2 (pt)
CA (1) CA2719623A1 (pt)
WO (1) WO2009120244A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8909325B2 (en) 2000-08-21 2014-12-09 Biosensors International Group, Ltd. Radioactive emission detector equipped with a position tracking system and utilization thereof with medical systems and in medical procedures
US9470801B2 (en) 2004-01-13 2016-10-18 Spectrum Dynamics Llc Gating with anatomically varying durations
US9040016B2 (en) 2004-01-13 2015-05-26 Biosensors International Group, Ltd. Diagnostic kit and methods for radioimaging myocardial perfusion
US10964075B2 (en) 2004-01-13 2021-03-30 Spectrum Dynamics Llc Gating with anatomically varying durations
CN1981210A (zh) 2004-01-13 2007-06-13 光谱动力学有限责任公司 多维图像重构
EP1778957A4 (en) 2004-06-01 2015-12-23 Biosensors Int Group Ltd OPTIMIZING THE MEASUREMENT OF RADIOACTIVE RADIATION ON SPECIAL BODY STRUCTURES
US9316743B2 (en) 2004-11-09 2016-04-19 Biosensors International Group, Ltd. System and method for radioactive emission measurement
US10136865B2 (en) 2004-11-09 2018-11-27 Spectrum Dynamics Medical Limited Radioimaging using low dose isotope
WO2008059489A2 (en) * 2006-11-13 2008-05-22 Spectrum Dynamics Llc Radioimaging applications of and novel formulations of teboroxime
US8837793B2 (en) 2005-07-19 2014-09-16 Biosensors International Group, Ltd. Reconstruction stabilizer and active vision
US8894974B2 (en) 2006-05-11 2014-11-25 Spectrum Dynamics Llc Radiopharmaceuticals for diagnosis and therapy
WO2008075362A2 (en) 2006-12-20 2008-06-26 Spectrum Dynamics Llc A method, a system, and an apparatus for using and processing multidimensional data
US8338788B2 (en) 2009-07-29 2012-12-25 Spectrum Dynamics Llc Method and system of optimized volumetric imaging
WO2011122947A1 (en) 2010-04-01 2011-10-06 Medical Technology Transfer Holding B.V. Staining composition
PL2830666T3 (pl) 2012-03-26 2021-03-08 Board Of Regents, The University Of Texas System Skuteczna synteza koniugatów etylenodicysteina-cukier do obrazowania i terapii
US10568589B2 (en) * 2012-06-04 2020-02-25 Ge Medical Systems Israel, Ltd Method and system for performing an imaging scan of a subject
US10939822B2 (en) 2013-01-24 2021-03-09 Tylerton International Holdings Inc. Body structure imaging
WO2015033317A2 (en) 2013-09-08 2015-03-12 Shlomo Ben-Haim Detection of reduced-control cardiac zones
CN106102583B (zh) 2014-01-10 2024-08-09 泰勒顿国际控股公司 瘢痕和纤维心脏区的检测
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US12396970B2 (en) 2021-08-20 2025-08-26 AltaThera Pharmaceuticals LLC Anti-arrhythmic compositions and methods
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
WO2021011471A1 (en) * 2019-07-12 2021-01-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of heart defects and conditions in pediatric patients
CN119613358A (zh) * 2024-11-21 2025-03-14 广东京豪生物制药有限公司 盐酸艾司洛尔的制备工艺

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4387103A (en) * 1980-11-28 1983-06-07 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
US4439356A (en) * 1981-03-03 1984-03-27 Syva Company Unsymmetrical fluorescein derivatives
US4556668A (en) * 1983-07-15 1985-12-03 American Hospital Supply Corporation Ethylenediamine derivatives of aryloxypropanolamine aryl esters having various medicinal properties
US5141739A (en) * 1986-07-03 1992-08-25 Advanced Magnetics, Inc. Delivery of x-ray contrast agents using receptor mediated endocytosis
US5188934A (en) * 1989-11-14 1993-02-23 Applied Biosystems, Inc. 4,7-dichlorofluorescein dyes as molecular probes
US5112595A (en) * 1990-12-21 1992-05-12 Mallinckrodt Medical, Inc. 99MTC(III) myocardial imaging agents and method of use
FR2721925B1 (fr) * 1994-06-30 1996-08-30 Cis Bio Int Derives halogenes de 1-phenoxy-3-n-alky-laminopropan-2 ol utilisables comme marqueurs des recepteurss b adrenergiques myocardiques et comme (b-bloquant)
GB2313310B (en) * 1995-01-19 1999-03-17 Cate Folkert Jan Ten Local delivery and monitoring of drugs
US5900228A (en) * 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6692724B1 (en) * 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
IL153218A0 (en) * 2000-06-02 2003-07-06 Univ Texas Ethylenedicysteine (ec) -drug conjugates
CA2427911A1 (en) * 2000-11-03 2002-05-10 Bristol Myers Squibb Company Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
US7303741B2 (en) 2002-09-23 2007-12-04 General Electric Company Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism
KR101086690B1 (ko) * 2002-11-07 2011-11-25 셀>포인트, 엘엘씨 에틸렌디시스테인（ｅｃ）－약물 콘쥬게이트, 조성물 및조직 특이적 질환 영상 방법
US20060258652A1 (en) * 2002-11-22 2006-11-16 Haj-Yehia Abdullah I Beta-blockers having antioxidant and no-donor activity
BRPI0414512B8 (pt) * 2003-09-17 2021-05-25 Board Of Regentes The Univ Of Texas System composição para reproduzir imagens de um pâncreas e uso desta
EP1745802A1 (en) * 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
US20080131517A1 (en) * 2006-09-01 2008-06-05 Abdel Fawzy Time-sustained-release formulations comprising a beta-blocker
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

Also Published As

Publication number Publication date
CA2719623A1 (en) 2009-10-01
WO2009120244A1 (en) 2009-10-01
EP2268320A1 (en) 2011-01-05
JP2011515467A (ja) 2011-05-19
CN102159253A (zh) 2011-08-17
AU2008353360A1 (en) 2009-10-01
US20130302245A1 (en) 2013-11-14
KR20100127845A (ko) 2010-12-06
US8440168B2 (en) 2013-05-14
EP2268320A4 (en) 2014-10-01
US20090238756A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
BRPI0822572A2 (pt) Terapia guiada por imagem de doença moicardial, composição manufaturamento e aplicações
BRPI0917567A2 (pt) tratamento de doença respiratória
EP2296593A4 (en) MEDICAL HEAD COVER
BRPI0812209A2 (pt) Partícula de liberação contendo agente de benefício
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0923823A2 (pt) Agente de colaboração.
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI0722004A2 (pt) Posto de saúde.
EP2351595A4 (en) Medical connection
BRPI1014160A2 (pt) Formulações de nanopartículas e aplicações das mesmas
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
IL212986A (en) Double-stranded oligonucleotide and a pharmaceutical composition
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
EP2323603A4 (en) THERAPEUTIC COMPRESSION CLOTHING
BRPI0913447A2 (pt) composição de éster, e, composição para cuidado pessoal.
BRPI0906611A2 (pt) Produtos implantáveis compreendendo nanopartículas.
BRPI0813212A2 (pt) Métodos de tratamento de doenças e distúrbios mediados por serotonina
BRPI1010768A2 (pt) composto, e, composição farmacêutica.
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
EP2207803A4 (en) Cd9-specific human antibodies
BRPI1006821A2 (pt) composições para o tratamento da doença de refluxo gastro-esofágico (gerd).
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
EP2240213A4 (en) SURFACE-FINISHED METAL IMPLANT
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.